Regeneron Pharmaceuticals Inc to Provide Updates Across its Oncology Portfolio Call Transcript
Good day, and thank you for standing by. Welcome to the Regeneron ESMO 2022 Investor Event. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Ryan Crowe, Head of Investor Relations. Please go ahead.
Thank you, Catherine. Good morning, good afternoon and good evening to everyone listening around the globe. Welcome to our ESMO 2022 Investor Call.
I would like to remind you that remarks made on this call today include forward-looking statements about Regeneron's business and research development programs, anticipated milestones and regulatory matters. Each forward-looking statement is subject to risks and uncertainties that could cause the actual results and events to differ materially from those projected in that statement. A more complete description of these and other material risks can be found in Regeneron's SEC filings. Regeneron does not undertake any obligation to update publicly
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |